(ASTH) Astrana Health - Overview

Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NASDAQ (USA) | Market Cap: 1.393m USD | Total Return: -5.3% in 12m

Medical Care, Care Coordination, Physician Network
Total Rating 36
Safety 54
Buy Signal 0.22
Medical Care Facilities
Industry Rotation: -13.2
Market Cap: 1.39B
Avg Turnover: 9.69M USD
ATR: 4.90%
Peers RS (IBD): 46.8
Risk 5d forecast
Volatility60.6%
Rel. Tail Risk-16.8%
Reward TTM
Sharpe Ratio0.20
Alpha-25.84
Character TTM
Beta0.653
Beta Downside0.935
Drawdowns 3y
Max DD70.96%
CAGR/Max DD-0.16
EPS (Earnings per Share) EPS (Earnings per Share) of ASTH over the last years for every Quarter: "2021-03": 0.3, "2021-06": 0.28, "2021-09": 0.69, "2021-12": 0.3, "2022-03": 0.31, "2022-06": 0.25, "2022-09": 0.56, "2022-12": -0.06, "2023-03": 0.31, "2023-06": 0.28, "2023-09": 0.47, "2023-12": 0.26, "2024-03": 0.31, "2024-06": 0.4, "2024-09": 0.33, "2024-12": 0.367, "2025-03": 0.3424, "2025-06": 0.19, "2025-09": 0.01, "2025-12": 0.4243, "2026-03": 0,
EPS CAGR: -29.69%
EPS Trend: -22.6%
Last SUE: -0.99
Qual. Beats: 0
Revenue Revenue of ASTH over the last years for every Quarter: 2021-03: 176.058, 2021-06: 175.638, 2021-09: 227.117, 2021-12: 195.1, 2022-03: 263.258, 2022-06: 269.697, 2022-09: 317.001, 2022-12: 294.208, 2023-03: 337.244, 2023-06: 348.209, 2023-09: 348.173, 2023-12: 353.036, 2024-03: 404.356, 2024-06: 486.265, 2024-09: 478.71, 2024-12: 665.209, 2025-03: 620.39, 2025-06: 654.808, 2025-09: 956.048, 2025-12: 950.526, 2026-03: null,
Rev. CAGR: 40.83%
Rev. Trend: 96.7%
Last SUE: 0.95
Qual. Beats: 1

Warnings

High Debt/EBITDA (5.0) with thin interest coverage (1.7)

Volatile

Tailwinds

No distinct edge detected

Description: ASTH Astrana Health

Astrana Health, Inc. (ASTH) is a US-based healthcare management company providing medical care services. The company operates through three segments: Care Partners, Care Delivery, and Care Enablement. This structure is common in the healthcare services sector, allowing for diversified service offerings and revenue streams.

ASTH coordinates care for various stakeholders, including patients, physicians, hospitals, and health plans. Its physician network includes primary care, specialist, and hospitalist physicians. The company primarily serves patients with private insurance, Medicare, Medicaid, and HMO plans, reflecting typical payment models in the healthcare industry. Astrana Health, Inc. was founded in 1994 and changed its name from Apollo Medical Holdings, Inc. in February 2024.

Further research on ValueRay can provide a deeper understanding of ASTHs financial performance and market position.

Headlines to Watch Out For
  • Medicare and Medicaid reimbursement rates impact revenue
  • Physician network expansion drives patient growth
  • Regulatory changes in healthcare sector create uncertainty
  • Value-based care model adoption boosts profitability
  • Competition for physician groups affects market share
Piotroski VR‑10 (Strict) 4.5
Net Income: 22.5m TTM > 0 and > 6% of Revenue
FCF/TA: 0.05 > 0.02 and ΔFCF/TA 1.59 > 1.0
NWC/Revenue: 7.80% < 20% (prev 13.41%; Δ -5.62% < -1%)
CFO/TA 0.05 > 3% & CFO 114.6m > Net Income 22.5m
Net Debt (648.7m) to EBITDA (128.7m): 5.04 < 3
Current Ratio: 1.40 > 1.5 & < 3
Outstanding Shares: last quarter (49.5m) vs 12m ago 3.33% < -2%
Gross Margin: 9.73% > 18% (prev 0.13%; Δ 959.5% > 0.5%)
Asset Turnover: 178.1% > 50% (prev 150.2%; Δ 27.91% > 0%)
Interest Coverage Ratio: 1.66 > 6 (EBITDA TTM 128.7m / Interest Expense TTM 49.9m)
Altman Z'' 1.69
A: 0.11 (Total Current Assets 863.3m - Total Current Liabilities 615.3m) / Total Assets 2.22b
B: 0.14 (Retained Earnings 308.4m / Total Assets 2.22b)
C: 0.05 (EBIT TTM 82.9m / Avg Total Assets 1.79b)
D: 0.19 (Book Value of Equity 308.4m / Total Liabilities 1.66b)
Altman-Z'' Score: 1.69 = BB
Beneish M -2.40
DSRI: 0.80 (Receivables 407.6m/324.8m, Revenue 3.18b/2.03b)
GMI: 1.37 (GM 9.73% / 13.34%)
AQI: 1.15 (AQ_t 0.57 / AQ_t-1 0.49)
SGI: 1.56 (Revenue 3.18b / 2.03b)
TATA: -0.04 (NI 22.5m - CFO 114.6m) / TA 2.22b)
Beneish M-Score: -2.40 (Cap -4..+1) = BBB
What is the price of ASTH shares? As of April 08, 2026, the stock is trading at USD 27.75 with a total of 569,352 shares traded.
Over the past week, the price has changed by +13.17%, over one month by +12.26%, over three months by -1.53% and over the past year by -5.26%.
Is ASTH a buy, sell or hold? Astrana Health has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy ASTH.
  • StrongBuy: 9
  • Buy: 0
  • Hold: 3
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the ASTH price?
Analysts Target Price 36 29.7%
Astrana Health (ASTH) - Fundamental Data Overview as of 04 April 2026
P/E Trailing = 54.4565
P/E Forward = 23.0415
P/S = 0.4378
P/B = 1.7488
Revenue TTM = 3.18b USD
EBIT TTM = 82.9m USD
EBITDA TTM = 128.7m USD
Long Term Debt = 990.9m USD (from longTermDebt, last quarter)
Short Term Debt = 55.7m USD (from shortTermDebt, last quarter)
Debt = 1.08b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 648.7m USD (from netDebt column, last quarter)
Enterprise Value = 2.04b USD (1.39b + Debt 1.08b - CCE 429.5m)
Interest Coverage Ratio = 1.66 (Ebit TTM 82.9m / Interest Expense TTM 49.9m)
EV/FCF = 18.98x (Enterprise Value 2.04b / FCF TTM 107.6m)
FCF Yield = 5.27% (FCF TTM 107.6m / Enterprise Value 2.04b)
FCF Margin = 3.38% (FCF TTM 107.6m / Revenue TTM 3.18b)
Net Margin = 0.71% (Net Income TTM 22.5m / Revenue TTM 3.18b)
Gross Margin = 9.73% ((Revenue TTM 3.18b - Cost of Revenue TTM 2.87b) / Revenue TTM)
Gross Margin QoQ = 8.27% (prev 8.53%)
Tobins Q-Ratio = 0.92 (Enterprise Value 2.04b / Total Assets 2.22b)
Interest Expense / Debt = 1.63% (Interest Expense 17.5m / Debt 1.08b)
Taxrate = 12.58% (944k / 7.51m)
NOPAT = 72.5m (EBIT 82.9m * (1 - 12.58%))
Current Ratio = 1.40 (Total Current Assets 863.3m / Total Current Liabilities 615.3m)
Debt / Equity = 1.38 (Debt 1.08b / totalStockholderEquity, last quarter 779.3m)
Debt / EBITDA = 5.04 (Net Debt 648.7m / EBITDA 128.7m)
Debt / FCF = 6.03 (Net Debt 648.7m / FCF TTM 107.6m)
Total Stockholder Equity = 766.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.26% (Net Income 22.5m / Total Assets 2.22b)
RoE = 2.93% (Net Income TTM 22.5m / Total Stockholder Equity 766.4m)
RoCE = 4.72% (EBIT 82.9m / Capital Employed (Equity 766.4m + L.T.Debt 990.9m))
RoIC = 4.84% (NOPAT 72.5m / Invested Capital 1.50b)
WACC = 5.29% (E(1.39b)/V(2.47b) * Re(8.28%) + D(1.08b)/V(2.47b) * Rd(1.63%) * (1-Tc(0.13)))
Discount Rate = 8.28% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.09%
[DCF] Terminal Value 86.80% ; FCFF base≈82.2m ; Y1≈86.3m ; Y5≈100.8m
[DCF] Fair Price = 41.89 (EV 2.98b - Net Debt 648.7m = Equity 2.33b / Shares 55.6m; r=6.0% [WACC]; 5y FCF grow 5.32% → 3.0% )
EPS Correlation: -22.55 | EPS CAGR: -29.69% | SUE: -0.99 | # QB: 0
Revenue Correlation: 96.67 | Revenue CAGR: 40.83% | SUE: 0.95 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.65 | Chg7d=+0.650 | Chg30d=+0.650 | Revisions Net=-1 | Analysts=1
EPS current Year (2026-12-31): EPS=2.69 | Chg7d=+0.580 | Chg30d=+0.580 | Revisions Net=+1 | Growth EPS=+26.7% | Growth Revenue=+25.3%
EPS next Year (2027-12-31): EPS=2.99 | Chg7d=+0.380 | Chg30d=+0.380 | Revisions Net=+1 | Growth EPS=+11.2% | Growth Revenue=+9.7%
External Resources
Dataroma Stockcircle